Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
about
Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD)Biomarkers in drug discovery and development: from target identification through drug marketing.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Clinical trial simulation: a tool for understanding study failures and preventing them.Generating Virtual Patients by Multivariate and Discrete Re-Sampling TechniquesEvidence of effectiveness: how much can we extrapolate from existing studies?Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.A quantitative system pharmacology computer model for cognitive deficits in schizophreniaThe pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Models for disease progression: new approaches and uses.Disease progression and neuroscience.Model-based clinical drug development in the past, present and future: a commentary.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.Disease Progression Modeling: Key Concepts and Recent DevelopmentsModeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.Development of a placebo effect model combined with a dropout model for bipolar disorder.Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.Need for Outcome Scenario Analysis of Clinical Trials in Diabetes.
P2860
Q30983599-3AC94EEF-DF40-43AB-B301-0C35C00D88F2Q34990277-D8C02FAE-0BED-4D00-B442-A44C5ACB4BA4Q35118033-9828975A-EF6A-406B-8180-2AE2439A36AEQ35827649-7475A460-3F70-46B8-AF94-FDA5C2E61F3BQ36055589-630BF094-CB8D-4466-9B28-BB3F8D781F00Q36080108-2E94F0E2-823E-4DA6-88C2-5DC933437980Q36341627-805AB096-D8B9-429A-9236-57E6DD1B5876Q36341664-7FC72817-6B1B-4AEC-AC35-D12C9964200BQ36795559-B0030AA9-1F28-4778-9294-C52686BB763AQ37829947-5902F5B9-CA21-4C29-9A26-30F95A75AFBCQ37886138-2DC0DA3D-C65D-4A45-9EE2-0B366A6F1B80Q38012237-B627263B-E22A-4D27-82EA-0A4D5EDCAC99Q38099584-CFE5AF0E-D129-450D-9226-BD82CD0E15ACQ38188035-9CDBB458-39BA-4EA2-B0A1-8FB8923589B5Q39959170-2B785FE2-E029-4514-8CFA-169E50FD4B71Q41471506-0AAF27B9-E177-4F08-89D3-DB1CAF978188Q41639443-1CB0B769-65E0-4B91-9BA1-AC2298820C12Q43199874-3DD61C4E-382C-4575-BEF8-243A38529031Q43480141-12EC6284-06BD-4792-9E02-20F6ED431BB4Q43985737-E466B302-3A50-4320-9846-24CAFA177E00Q46727005-42420F86-5D9E-497E-99B5-263ADBE6E9CAQ48017570-85DA4367-C46E-4EDC-979B-C47E8756741DQ51780022-621AD165-0D2A-49A9-8ED8-4250DE67533E
P2860
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Prediction of the outcome of a ...... tic and pharmacodynamic model.
@en
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent
@nl
type
label
Prediction of the outcome of a ...... tic and pharmacodynamic model.
@en
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent
@nl
prefLabel
Prediction of the outcome of a ...... tic and pharmacodynamic model.
@en
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent
@nl
P2093
P356
P1476
Prediction of the outcome of a ...... etic and pharmacodynamic model
@en
P2093
P304
P356
10.1067/MCP.2000.110975
P407
P50
P577
2000-11-01T00:00:00Z